Related Experiment Video

Updated: May 10, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells

Liang Yu1, Yan-sheng Su, Jie Zhao

  • 1Department of Urology, Xijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an 710032, China.

FEBS Letters
|July 9, 2013
PubMed

Insights

Metastasis-associated protein 1 (MTA1) promotes docetaxel chemoresistance in prostate cancer by silencing the nuclear receptor NR4A1. Reducing MTA1 enhances chemotherapy effectiveness, suggesting it as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Epigenetic mechanisms are crucial in cancer chemoresistance.
  • Prostate cancer (PCa) often develops resistance to chemotherapy.
  • The nucleosome remodeling deacetylation (NuRD) complex is implicated in gene regulation.

Purpose of the Study:

  • To investigate the role of metastasis-associated protein 1 (MTA1) in docetaxel (DTX) chemoresistance in prostate cancer.
  • To elucidate the molecular mechanisms by which MTA1 influences chemoresistance.
  • To evaluate MTA1 as a potential therapeutic target for overcoming DTX resistance.

Main Methods:

  • Analyzing MTA1 expression in chemoresistant PCa.
  • Utilizing MTA1 knockdown and overexpression in PC-3 cells.
  • Assessing cell proliferation and docetaxel-induced cell death.
  • Investigating the interaction between MTA1, histone deacetylase 2 (HDAC2), and nuclear receptor NR4A1 transcription.

Main Results:

  • Upregulated MTA1 expression was observed in chemoresistant prostate cancer.
  • MTA1 knockdown inhibited PC-3 cell proliferation and increased sensitivity to docetaxel.
  • MTA1 overexpression conferred docetaxel resistance to PC-3 cells.
  • MTA1 was identified as a corepressor of NR4A1 transcription via interaction with HDAC2.

Conclusions:

  • MTA1 promotes docetaxel resistance in prostate cancer cells.
  • MTA1 functions as a chemoresistance promoter by repressing NR4A1 transcription.
  • MTA1 represents a potential therapeutic target for enhancing docetaxel efficacy in prostate cancer.
Keywords:
ChemoresistanceMetastasis-associated protein 1 (MTA1)Nucleosome remodeling deacetylation (NuRD) complexProstate cancer (PCa)

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...